EGEnise Ece Gurdal

Enise Ece Gurdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Enise Ece Gurdal has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Rise of Artificial Intelligence in Pharma: Shaping the Future of Drug Discovery

    by Ayça Dedeoglu Erdogan, Armanç Mat, Enise Ece Gürdal, Meric Koksal Akkoc

    Drug discovery as an important scientific area that serves human health, requires continuous advancement for improved quality of life and survival rates. However, drug discovery is a long and expensive process. The studies aimed at dealing with these problems have enabled to combination of AI with drug development stages. For every step of the R&D process, AI plays a vital role in facilitating and accelerating the work. Firstly, AI methods (deep learning and convolutional neural networks) help predict the 3D structure of an unresolved protein making it easier for the rational design of compounds to target a specific protein among other potential outcomes. After estimation of the protein structure of interest, it is also possible to determine the protein-ligand interactions by utilizing AI technologies like random forest. The other stage, namely finding the hit compounds is also possible through AI-assisted QSAR models such as deep neural networks. Besides, there are many AI methods (k-nearest neighbor and support vector machines) for ADMET prediction to optimize lead compounds. Finally, AI techniques also aid in choosing the most suitable synthesis plan. In the light of the latest advances, AI has become the focus of the pharmaceutical industry. However, despite the potential benefits of AI in drug discovery, several challenges must be considered including the availability of suitable data and bioethical issues. This article provides a comprehensive review of the benefits and applications of AI in various stages of drug discovery. In addition, the open-source act model and bioethical issues are also discussed.

  • Open Access

    In Silico Target Prediction Of 6-Gingerol And Similar Compounds As Potential Anticancer Agents

    by Nour Osama Al-Massri, Enise Ece Gurdal, Gulcin Tugcu

    Ginger (Zingiber officinale Roscoe) has been widely recognized for its culinary and medicinal applications; however, its potential anticancer activity remains understudied. This research aimed to identify novel lead compounds exhibiting high bioavailability and low toxicity, akin to 6-gingerol, through an in silico screening approach using ChemMine Tools depending on the PubChem fingerprints. The screened compounds were further analyzed using target fishing servers to identify putative kinase targets. Molecular docking studies were conducted on selected kinases including BRAF, JAK1/2, ERK1(MAPK3), and p38γ. Computational analysis was performed to evaluate the pharmacokinetics, drug-likeness, and toxicity profiles of the compounds, shedding light on their safety and bioavailability. Notably, the following compounds exhibited promising anticancer potential: 6-gingerol, vanylglycol, vanillylmandelic acid, L-(+)-vanilmandelic acid, dehydrozingerone, 2-methoxyestrone, methylvanillate, dihydroconiferyl aldehyde, pratensein, acetovanillone, acetosyringone, licochalcone B, isoferulic acid, curcumin PE, and coniferaldehyde. These findings suggest that these compounds warrant further investigation as potential candidates for anti-cancer therapies and should be considered for future lead optimization studies.


  • Correction to “Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer’s Disease”

    by Bengisu Turgutalp, Prabesh Bhattarai, Tugba Ercetin, Chiara Luise, Rengin Reis, Enise Ece Gurdal, Andreas Isaak, Derya Biriken, Elisabeth Dinter, Hande Sipahi, et al.

  • Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer’s Disease

    by Bengisu Turgutalp, Prabesh Bhattarai, Tugba Ercetin, Chiara Luise, Rengin Reis, Enise Ece Gurdal, Andreas Isaak, Derya Biriken, Elisabeth Dinter, Hande Sipahi, et al.

    Drug development efforts that focused on single targets failed to provide effective treatment for Alzheimer's disease (AD). Therefore, we designed cholinesterase inhibition (ChEI)-based multi-target-directed ligands (MTDLs) to simultaneously target AD-related receptors. We built a library of 70 compounds, sequentially screened for ChEI, and determined σ1R, σ2R, NMDAR-GluN2B binding affinities, and P2X7R antagonistic activities. Nine fulfilled in silico drug-likeness criteria and did not display toxicity in three cell lines. Seven displayed cytoprotective activity in two stress-induced cellular models. Compared to donepezil, six showed equal/better synaptic protection in a zebrafish model of acute amyloidosis-induced synaptic degeneration. Two P2X7R antagonists alleviated the activation state of microglia in vivo. Permeability studies were performed, and four did not inhibit CYP450 3A4, 2D6, and 2C9. Therefore, four ChEI-based lead MTDLs are promising drug candidates for synaptic integrity protection and could serve as disease-modifying AD treatment. Our study also proposes zebrafish as a useful preclinical tool for drug discovery and development.


  • Lead Optimization and Structure–Activity Relationship Studies on Myeloid Ecotropic Viral Integration Site 1 Inhibitor

    by Bengisu Turgutalp, Merve Uslu, Sinem Helvacioglu, Mohammad Charehsaz, Enise Ece Gurdal, Wolfgang Sippl, Fatih Kocabas, Mine Yarim

    The pivotal role of the myeloid ecotropic viral integration site 1 (MEIS1) transcriptional factor was reported in cardiac regeneration and hematopoietic stem-cell (HSC) regulation with our previous findings. MEIS1 as a promising target in the context of pharmacological inhibition, we identified a potent myeloid ecotropic viral integration site (MEIS) inhibitor, MEISi-1, to induce murine and human HSC expansion ex vivo and in vivo. In this work, we performed lead optimization on MEISi-1 by synthesizing 45 novel analogues. Structure–activity relationship studies revealed the significance of a para-methoxy group on ring A and a hydrophobic moiety at the meta position of ring B. Obtained biological data were supported by inhibitor docking and molecular dynamics simulation studies. Eleven compounds were depicted as potent inhibitors demonstrating a better inhibitory profile on MEIS1 and target genes Meis1, Hif-1α, and p21. Among those, 4h, 4f, and 4b were the most potent inhibitors. The predicted pharmacokinetics properties fulfill drug-likeness criteria. In addition, compounds exerted neither cytotoxicity on human dermal fibroblasts nor mutagenicity.


  • Design, synthesis, and molecular docking of novel 3,5‐disubstituted‐1,3,4‐oxadiazole derivatives as iNOS inhibitors

    by Meric Koksal, Ayca Dedeoglu‐Erdogan, Marwa Bader, Enise E. Gurdal, Wolfgang Sippl, Rengin Reis, Melda Ozgurbuz, Hande Sipahi, Turgay Celik

    To obtain new anti‐inflammatory agents, recent studies have aimed to replace the carboxylate functionality of nonsteroidal anti‐inflammatory drugs with less acidic heterocyclic bioisosteres like 1,3,4‐oxadiazole to protect the gastric mucosa from free carboxylate moieties. In view of these observations, we designed and synthesized a series of 3,5‐disubstituted‐1,3,4‐oxadiazole derivatives as inhibitors of prostaglandin E2 (PGE2) and NO production with an improved activity profile. As initial screening, and to examine the anti‐inflammatory activities of the compounds, the inhibitions of the productions of lipopolysaccharide‐induced NO and PGE2 in RAW 264.7 macrophages were evaluated. The biological assays showed that, compared with indomethacin, compounds 5a, 5g, and 5h significantly inhibited NO production with 12.61 ± 1.16, 12.61 ± 1.16, and 18.95 ± 3.57 µM, respectively. Consequently, the three compounds were evaluated for their in vivo anti‐inflammatory activities. Compounds 5a, 5g, and 5h showed a potent anti‐inflammatory activity profile almost equivalent to indomethacin at the same dose in the carrageenan‐induced paw edema test. Moreover, the treatment with 40 mg/kg of 5h produced significant anti‐inflammatory activity data. Furthermore, docking studies were performed to reveal possible interactions with the inducible nitric oxide synthase enzyme. Docking results were able to rationalize the biological activity data of the studied inhibitors. In summary, our data suggest that compound 5h is identified as a promising candidate for further anti‐inflammatory drug development with an extended safety profile.


  • Synthesis, Antimicrobial, Antioxidant and Molecular Docking Studies on Novel 6-Methoxybenzothiazole-piperazine Derivatives with Propanamide Chain

    by Nesrin Atiah Alhusadi, Bengisu Turgutalp, Inci Deniz, Ebru Turkoz Acar, Hande Sipahi, Mine Yarim, Enise Ece Gurdal

    Background: Infectious diseases are a major threat in the developing world and the discovery of novel antimicrobial agents remains to be crucial due to acquired resistance by the microorganisms. Additionally, various diseases can be prevented with antioxidant agents as they can eliminate the harmful effects of reactive oxygen species. Objective: In this study, it was aimed to synthesize novel compounds bearing N-(6- methoxybenzothiazol-2-yl)-3-(4-substitued piperazinyl)propanamide backbone that had antimicrobial and antioxidant activities. Mechanisms of activity were aimed to be revealed by docking studies. Methods: Antimicrobial activities were tested by agar-based disc diffusion assay, and antioxidant activities were determined by CUPRAC assay. Results: In agar-based disc diffusion assay, the most active compounds were 2b and 2e against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Candida albicans. Compounds 2e and 2j showed promising antioxidant activity in CUPRAC assay. Docking studies were performed to optimize the interactions of compounds with DNA gyrase subunit B of S. aureus. Under the light of docking studies, a new compound with potential GyrB inhibition was designed. Antioxidant activity was also supported by docking studies on superoxide dismutase 1 enzyme in which interactions with key residues were observed. Conclusion: Ten novel benzothiazole-piperazine derivatives were synthesized and their antimicrobial and antioxidant activities were evaluated. Superoxide dismutase 1 enzyme was suggested to be a possible target for the antioxidant activity of the series.


  • Synthesis, anti‐inflammatory activity, and molecular docking studies of some novel Mannich bases of the 1,3,4‐oxadiazole‐2(3H)‐thione scaffold

    by Tugce Ozyazici, Enise E. Gurdal, Duygu Orak, Hande Sipahi, Tuba Ercetin, Hayrettin O. Gulcan, Meric Koksal

    A series of novel ibuprofen and salicylic acid‐based 3,5‐disubstituted‐1,3,4‐oxadiazole‐2(3H)‐thione derivatives was synthesized, and they were evaluated as potential anti‐inflammatory agents. Following the structure identification studies employing IR, 1H nuclear magnetic resonance (NMR), 13C NMR, and elemental analysis, the title compounds were tested by cyclooxygenase (COX)‐1 and COX‐2 inhibition assays concomitant to lipopolysaccharide (LPS)‐induced nitric oxide and prostaglandin production prevention experiments. The results indicated that the majority of the compounds displayed either a superior or comparable activity in preventing both LPS‐induced NO production and COX‐1 activity in comparison to the activities of the reference molecules. Furthermore, docking studies were also performed to reveal possible interactions with the COX enzymes.


  • Synthesis and Cytotoxicity Studies on Novel Piperazinylacetamides

    by Eman Bobtaina, Enise Ece Gurdal, Irem Durmaz, Rengul Cetin Atalay, Mine Yarim

    Background: In this study, nine novel compounds, bearing N-[2-(4-substituted piperazine-1-yl)acetyl]-N’-[bis-(4-fluorophenyl)methyl]piperazine structures were synthesized. Methods: Their cytotoxic properties were evaluated in vitro by NCI-60 Sulforhodamine B (SRB) assay against human cancer cell lines: Huh7 (hepatocellular), MCF7 (breast) and HCT116 (colorectal). Results and Conclusion: According to the activity data, most of the compounds are more cytotoxic than 5-fluorouracil against Huh7 and HCT116 cancer cell lines.

  • Synthesis of Novel Benzothiazole-Piperazine Derivatives and Their Biological Evaluation as Acetylcholinesterase Inhibitors and Cytotoxic Agents

    by Enise Ece Gurdal, Bengisu Turgutalp, Hayrettin Ozan Gulcan, Tugba Ercetin, Mustafa Fethi Sahin, Irem Durmaz, Rengul Cetin Atalay, Quoc Dat Nguyen, Wolfgang Sippl, Mine Yarim

    Objective and Method: A new series of benzothiazole-piperazine derivatives was synthesized and a complete chemical characterization of the novel compounds was provided. In vitro cytotoxic activities were screened against colorectal (HCT-116), breast (MCF-7) and hepatocellular (Huh7) cancer cell lines by Sulforhodamine B assay. Result and Discussion: All compounds showed cytotoxic activity against hepatocellular (Huh7) and breast (MCF-7) cancer cell lines. Dihalo substituted benzylpiperazine derivatives (2a, 2e) had the highest cytotoxic activities in all the tested cell lines. In addition, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of synthesized compounds were investigated by in vitro Ellman's method. Compound 2j led to moderate and selective inhibition against AChE. Docking study was utilized to understand the binding mode of compound 2j in comparision with donepezil on AChE. The other tested compounds showed weak or no inhibition against AChE as promising anticancer agents.